Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prochlorperazine is a first-generation (typical) antipsychotic of the phenothiazine class. It is primarily used to treat severe nausea and vomiting, schizophrenia, and non-psychotic anxiety. Prochlorperazine acts mainly as a dopamine D2 receptor antagonist in the brain, which reduces dopaminergic neurotransmission responsible for psychotic symptoms and triggers for vomiting. It also exhibits antagonistic activity at histaminergic, cholinergic (muscarinic), and alpha-1 adrenergic receptors. Compared to other phenothiazines, it is less sedating and has a lower risk of causing hypotension or potentiating CNS depressants[4][5][6]. The drug is available in oral tablets (including dissolvable forms), rectal suppositories, and injectable formulations[4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prochlorperazine.